HDAC9 and cancer: HDAC inhibitors have thus emerged as promising anti-cancer agents, capable of reactivating TSGs and sensitizing cancer cells to apoptosis and immune recognition by restoring proper acetylation balance (Bouyahya et al. 2022b).